• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    6/12/24 4:31:07 PM ET
    $CPHI
    $ENTO
    $HOTH
    $IONM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CPHI alert in real time by email

    Gainers

    • Holdco Nuvo Group DG (NASDAQ:NUVO) shares increased by 21.5% to $1.92 during Wednesday's after-market session. The company's market cap stands at $63.8 million.
    • Entero Therapeutics (NASDAQ:ENTO) shares moved upwards by 8.69% to $2.25. The company's market cap stands at $6.1 million.
    • OneMedNet (NASDAQ:ONMD) shares moved upwards by 7.4% to $1.45. The market value of their outstanding shares is at $34.5 million.
    • China Pharma Holdings, Inc. Common Stock (AMEX:CPHI) stock increased by 5.92% to $0.29.
    • Nutex Health (NASDAQ:NUTX) stock increased by 5.53% to $0.57. The market value of their outstanding shares is at $28.3 million.
    • Inspire Veterinary (NASDAQ:IVP) stock increased by 5.05% to $1.87. The company's market cap stands at $1.8 million.

    Losers

    • Assure Hldgs (NASDAQ:IONM) shares fell 38.4% to $0.32 during Wednesday's after-market session. The company's market cap stands at $2.8 million. As per the press release, Q1 earnings came out 3 days ago.
    • RenovoRx (NASDAQ:RNXT) stock declined by 10.26% to $1.05. The company's market cap stands at $25.1 million.
    • Vigil Neuroscience (NASDAQ:VIGL) shares declined by 5.58% to $4.4. The company's market cap stands at $165.3 million.
    • Hoth Therapeutics (NASDAQ:HOTH) shares decreased by 5.01% to $0.94. The company's market cap stands at $4.5 million.
    • TRACON Pharma (NASDAQ:TCON) shares fell 5.0% to $0.95. The market value of their outstanding shares is at $2.5 million.
    • Rezolute (NASDAQ:RZLT) shares declined by 4.93% to $5.21. The market value of their outstanding shares is at $209.1 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $CPHI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CPHI
    $ENTO
    $HOTH
    $IONM

    CompanyDatePrice TargetRatingAnalyst
    Rezolute Inc.
    $RZLT
    3/25/2026$5.00Neutral → Outperform
    Wedbush
    Rezolute Inc.
    $RZLT
    12/11/2025$2.00Buy → Hold
    Craig Hallum
    Rezolute Inc.
    $RZLT
    12/11/2025Overweight → Neutral
    Cantor Fitzgerald
    Rezolute Inc.
    $RZLT
    12/11/2025$1.00Outperform → Neutral
    Wedbush
    Vigil Neuroscience Inc.
    $VIGL
    5/28/2025$8.00Buy → Hold
    Stifel
    Vigil Neuroscience Inc.
    $VIGL
    12/4/2024Outperform
    William Blair
    Nutex Health Inc.
    $NUTX
    11/12/2024$45.00 → $50.00Buy
    Maxim Group
    Rezolute Inc.
    $RZLT
    11/5/2024$12.00Outperform
    Wedbush
    More analyst ratings

    $CPHI
    $ENTO
    $HOTH
    $IONM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum

    Patent Expands Protection for the Company's RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System  RenovoRx Currently Holds a Strong and Growing Global Intellectual Property Portfolio with 19 Issued or Allowed Patents and 14 Pending Patents Supporting the Commercialization of the RenovoCath Device MOUNTAIN VIEW, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that the Japan Patent Office (JPO) has issued a Notice of Allowance for the Company's first Japane

    4/8/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OneMedNet Announces Strong 2025 Financials and Advances AI-Driven iRWD™ powered by Palantir Foundry enabling Conversational Search on Real-Time Medical Data

    MINNEAPOLIS, April 06, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (NASDAQ:ONMD) (the "OneMedNet," the "Company," "we," "us" or "our"), a leading provider of regulatory decision-grade, AI-Driven Real-World Data (RWD), highlights its 2025 results, with robust revenue growth from the prior year, a strengthened balance sheet, and continued commercial momentum driven by Palantir Foundry enabled conversational search on Real-Time medical data from OneMedNet's rapidly growing network. 2025 Financial Highlights: RWD Revenue Growth: RWD revenue increased 329% year-over-year, rising from $292,000 in 2024 to $1,254,000 in 2025, reflecting strong market demand and increased commercial traction.

    4/6/26 8:50:00 AM ET
    $ONMD
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Hoth Therapeutics Announces Closing of $2.0 Million Registered Direct Offering

    NEW YORK, April 2, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ:HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs, today announced the closing of its previously announced registered direct offering for the purchase and sale of an aggregate of 2,857,144 shares of its common stock (or common stock equivalents in lieu thereof) at an offering price of $0.70 per share of common stock (or per common stock equivalent in lieu thereof). Additionally, in a concurrent private placement, the Company issued and sold unregistered warrants to purchase up to an aggregate of 2,857,144 shares of common stock at an exercise price of $0.

    4/2/26 4:05:00 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPHI
    $ENTO
    $HOTH
    $IONM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rezolute upgraded by Wedbush with a new price target

    Wedbush upgraded Rezolute from Neutral to Outperform and set a new price target of $5.00

    3/25/26 8:24:55 AM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Craig Hallum with a new price target

    Craig Hallum downgraded Rezolute from Buy to Hold and set a new price target of $2.00

    12/11/25 3:51:30 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rezolute downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Rezolute from Overweight to Neutral

    12/11/25 12:30:42 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPHI
    $ENTO
    $HOTH
    $IONM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vo Thomas T.

    4 - Nutex Health Inc. (0001479681) (Issuer)

    4/10/26 4:18:36 PM ET
    $NUTX
    Real Estate

    SEC Form 4 filed by Bagai Shaun

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/7/26 8:00:06 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Voll Mark

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    4/7/26 8:00:05 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPHI
    $ENTO
    $HOTH
    $IONM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Legal Officer-Healthcare Montgomery Pamela W. bought $7,021 worth of shares (79 units at $88.87), increasing direct ownership by 3% to 2,758 units (SEC Form 4)

    4 - Nutex Health Inc. (0001479681) (Issuer)

    3/16/26 3:02:43 PM ET
    $NUTX
    Real Estate

    Chief Medical Officer Agah Ramtin bought $9,975 worth of shares (10,000 units at $1.00), increasing direct ownership by 1% to 798,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/22/26 7:00:18 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Agah Ramtin bought $8,424 worth of shares (9,795 units at $0.86), increasing direct ownership by 1% to 788,460 units (SEC Form 4)

    4 - RenovoRx, Inc. (0001574094) (Issuer)

    1/5/26 7:00:02 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPHI
    $ENTO
    $HOTH
    $IONM
    SEC Filings

    View All

    SEC Form D filed by RenovoRx Inc.

    D - RenovoRx, Inc. (0001574094) (Filer)

    4/9/26 10:19:11 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hoth Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    8-K - Hoth Therapeutics, Inc. (0001711786) (Filer)

    4/2/26 4:18:12 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Hoth Therapeutics Inc.

    424B5 - Hoth Therapeutics, Inc. (0001711786) (Filer)

    4/2/26 1:39:13 PM ET
    $HOTH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPHI
    $ENTO
    $HOTH
    $IONM
    Leadership Updates

    Live Leadership Updates

    View All

    RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

    Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced continued commercial progress, with

    2/27/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer

    MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or "the Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company's Chief Financial Officer, effective February 1, 2026. Mr. Voll brings more than three decades of financial leadership experience to RenovoRx, with a strong track record for guiding high-growth public companies through periods of commercial buildout and strategic development. He has served as Chief Financial Officer for multiple publicly traded technology co

    2/5/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx Strengthens Scientific Advisory Board (SAB) with Pancreatic Cancer Expert Timothy Donahue, MD

    MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx's scientific advisory board (SAB). Dr. Donahue is a nationally recognized expert in pancreatic cancer and serves as the Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases and as Chief of the Division of Surgical Oncology at the David Geffen School of Medicine. He also holds the Garry Shandling Ch

    11/6/25 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CPHI
    $ENTO
    $HOTH
    $IONM
    Financials

    Live finance-specific insights

    View All

    RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update

    RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the Middle of 2026, and Final Data Anticipated in 2027 With $13 Million on Hand, Company has the Funding, Business Plan, Leadership, and Infrastructure to Drive Growth and Shareholder Value Management to Host Conference Call Today at 4:30 p.m. ET MOUNTAIN VIEW, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced its f

    3/30/26 4:05:00 PM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET

    MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx's management team is expected to discuss the continued progress in RenovoCath adoption among U.S. cancer centers,

    3/20/26 8:30:00 AM ET
    $RNXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    NUTEX HEALTH REPORTS 2025 FINANCIAL RESULTS AND ANNOUNCES SECOND STOCK REPURCHASE PROGRAM

    FULL YEAR 2025 HIGHLIGHTS:Total revenue of $875.3 million for the year 2025 versus $479.9 million for the year 2024, an increase of 82.4%Net income attributable to Nutex Health of $70.8 million for 2025 versus net income of $52.1 million for 2024, an increase of $18.7 millionDiluted EPS of $10.48 for 2025 versus diluted EPS of $9.69 for 2024EBITDA of $168.6 million for 2025 versus $98.8 million for 2024, an increase of 70.6%Adjusted EBITDA of $259.6 million for 2025 versus $102.8 million for 2024, an increase of 152.6%Net cash from operating activities of $248.1 million for 2025HOUSTON, March 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ:NUTX), today ann

    3/5/26 6:33:00 PM ET
    $NUTX
    Real Estate

    $CPHI
    $ENTO
    $HOTH
    $IONM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by TRACON Pharmaceuticals Inc.

    SC 13G/A - Tracon Pharmaceuticals, Inc. (0001394319) (Subject)

    11/14/24 8:51:58 PM ET
    $TCON
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Rezolute Inc.

    SC 13G/A - Rezolute, Inc. (0001509261) (Subject)

    11/14/24 6:59:50 PM ET
    $RZLT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Vigil Neuroscience Inc.

    SC 13G/A - Vigil Neuroscience, Inc. (0001827087) (Subject)

    11/14/24 4:19:18 PM ET
    $VIGL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care